<DOC>
	<DOCNO>NCT01275105</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy , dose response brimonidine tartrate ophthalmic solution compare placebo prevention allergen-induced conjunctival redness use conjunctival allergen challenge ( CAC ) model . It hypothesize low-dose brimonidine tartrate ophthalmic solution effective vehicle prevention conjunctival redness induce conjunctival allergen challenge instill prior allergen challenge .</brief_summary>
	<brief_title>A Single-Center , Randomized , Double-Masked , Placebo Active Controlled , Dose-Ranging Evaluation Duration Action Brimonidine Tartrate Ophthalmic Solution Control Ocular Redness Induced Conjunctival Allergen Challenge ( CAC )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Oxymetazoline</mesh_term>
	<mesh_term>Phenylephrine</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Be least 18 year age ; If female , pregnant nursing Have positive skin test reaction cat hair , cat dander , grass , ragweed , dog dander , cockroach , dust mite , and/or tree within past 24 month ; Have calculate best correct visual acuity 0.6 logMAR good eye measure use ETDRS chart ; Have know contraindication sensitivity use study medication ( ) component ; Have ocular condition , opinion investigator , could affect subject 's safety ; Have presence active ocular infection ; Use specify disallow medication study appropriate prestudy washout period ; Have significant illness ; Have plan surgery ( ocular systemic ) trial period within 30 day ; Have use investigational drug device within 30 day study concurrently enrol another investigational drug device study within 30 day study ; Be female currently pregnant nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>